(Q34659408)

3 August 2017

Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist (English)

1 reference

3 August 2017

Crystal R Waites

1

1 reference

3 August 2017

Mark A Dominick

series ordinal

2

1 reference

3 August 2017

Thomas P Sanderson

series ordinal

3

1 reference

3 August 2017

Beth E Schilling

series ordinal

4

1 reference

3 August 2017

4 August 2007

1 reference

3 August 2017

Toxicological Sciences

1 reference

3 August 2017

100

1 reference

3 August 2017

1

1 reference

3 August 2017

248-258

1 reference

An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats

3 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

The mechanisms of action of PPARs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

Downregulated IRS-1 and PPARgamma in obese women with gestational diabetes: relationship to FFA during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious gluco

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

Hypoglycemia induced changes in cell death and cell proliferation in the organogenesis stage embryonic mouse heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

Roles of PPARs in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

PPARalpha agonist-induced rodent tumors: modes of action and human relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

The many faces of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

Metabolic and additional vascular effects of thiazolidinediones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

PPAR trilogy from metabolism to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

Peroxisome proliferator-activated receptor-alpha activation during pregnancy attenuates glucose-stimulated insulin hypersecretion in vivo by increasing insulin sensitivity, without impairing pregnancy-induced increases in beta-cell glucose sensing a

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

Activation of the nuclear receptor peroxisome proliferator-activated receptor gamma promotes brown adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FTOXSCI%2FKFM193

21 January 2018

Identifiers

DOI

10.1093/TOXSCI/KFM193

1 reference

3 August 2017

1 reference